查看文章

Patients suffering from non‐IgM light chain (AL) amyloidosis with severe cardiac dysfunction have a poor prognosis. A deep hematologic response can translate into a cardiac response and improve the survival of these patients. The Cyclophosphamide Bortezomib Dexamethasone (CyBorD) regimen is widely used as the first‐line regimen, but therapeutic options are limited in relapsed/refractory patients. Recently, Daratumumab has emerged as an attractive option in this indication and has been evaluated in several prospective trials (NCT02841033, NCT02816476, NCT03201965, NCT03283917). Patients with severe heart failure (stage IIIb) have been excluded from these studies and data regarding the use of Daratumumab in patients with severe cardiac involvement are lacking.

Evaluate the safety and efficacity of daratumumab in patients with cardiac stage III AL amyloidosis.